Accessibility Menu

Why Selecta Biosciences Tumbled 34% Today

Disappointing phase 2 data casts doubt on SEL-212's future.

By Todd Campbell Updated Oct 1, 2020 at 4:38PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.